Giudice, Elena
 Distribuzione geografica
Continente #
NA - Nord America 137
EU - Europa 82
AS - Asia 40
AF - Africa 1
Totale 260
Nazione #
US - Stati Uniti d'America 137
IT - Italia 32
CN - Cina 17
IE - Irlanda 17
SG - Singapore 16
SE - Svezia 9
FR - Francia 6
RU - Federazione Russa 5
KR - Corea 4
ES - Italia 3
GB - Regno Unito 3
NL - Olanda 3
CZ - Repubblica Ceca 2
AT - Austria 1
CI - Costa d'Avorio 1
FI - Finlandia 1
IN - India 1
IR - Iran 1
JP - Giappone 1
Totale 260
Città #
Ashburn 32
Chandler 27
Dublin 17
Rome 10
Singapore 9
New York 8
San Mateo 6
Washington 6
Moscow 5
Beijing 4
Milan 4
New Haven 4
Amsterdam 3
Asti 3
Boston 3
Busto Arsizio 3
Jeju City 3
Marseille 3
Princeton 3
Bari 2
Guidonia Montecelio 2
Nave 2
Olomouc 2
Osimo 2
Pamplona 2
Paris 2
Abidjan 1
Andover 1
Antwerp 1
Cambridge 1
Lappeenranta 1
Leawood 1
Madrid 1
Mountain View 1
Norwalk 1
Redwood City 1
Suyeong-gu 1
Tappahannock 1
Tokyo 1
Vienna 1
York 1
Zanjan 1
Totale 183
Nome #
Pembrolizumab for advanced cervical cancer: safety and efficacy 38
Bevacizumab as maintenance treatment in BRCA mutated patients with advanced ovarian cancer: A large, retrospective, multicenter case-control study 35
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 33
Evolution of Clinical Trials in Ovarian Cancer Management over the Past 20 Years: Never Settle Down, Always Go beyond 30
PARP Inhibitors Resistance: Mechanisms and Perspectives 25
Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon? 22
Recent progress in the use of pharmacotherapy for endometrial cancer 22
Advanced and recurrent endometrial cancer: State of the art and future perspectives 17
Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives 16
Management of stage III and IVa uterine cancer 15
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 13
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 6
Genome tumor profiling in endometrial cancer and clinical relevance in endometrial cancer management: A retrospective single-center experience 4
Totale 276
Categoria #
all - tutte 2.014
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.014


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212 0 0 0 0 0 0 1 0 0 0 1 0
2021/202225 0 0 0 5 0 0 1 7 2 1 2 7
2022/202384 6 9 2 9 2 8 4 3 6 9 19 7
2023/2024157 4 25 17 16 4 21 19 3 5 5 18 20
2024/20258 8 0 0 0 0 0 0 0 0 0 0 0
Totale 276